YELESWARAM KRISHNASWAMY (Chief Development Officer) sold 6.9% of their position (19.86K shares) of RAPPORT THERAPEUTICS, INC. on the open market
Open‑market sale worth $695.8K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 4/14/2026ACC: 0001193125-26-154908
Officer· Chief Development Officer
Since Feb 2026
-19.86K
Net shares
Net seller
$695.8K
Total sold
3
Open market trades
0B · 3S
3
Total transactions
19.86K disposed
Non-Derivative Transactions3
Common Stock
Direct
Shares
−500.00
Price / share
$34.98
Trade value
$17.49K
% of position
0.2%
4/10/2026
286.52K→286.02K
Common Stock
Direct
Shares
−9.16K
Price / share
$34.97
Trade value
$320.54K
% of position
3.2%
4/13/2026
286.02K→276.85K
Common Stock
Direct
Shares
−10.20K
Price / share
$35.08
Trade value
$357.80K
% of position
3.7%
4/14/2026
276.85K→266.65K
Total
Net shares
−19.86K
Net value
-$695.82K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 4/10/2026 | S · Sale | −500.00 | $34.98 | $17.49K | 0.2% | 286.52K | 286.02K |
| Common Stock Direct | 4/13/2026 | S · Sale | −9.16K | $34.97 | $320.54K | 3.2% | 286.02K | 276.85K |
| Common Stock Direct | 4/14/2026 | S · Sale | −10.20K | $35.08 | $357.80K | 3.7% | 276.85K | 266.65K |
| Total | −19.86K | -$695.82K | ||||||
Derivative Transactions0
No derivative transactions reported